Prestige Consumer Healthcare (PBH) - Long-Term Debt to Capital

Corporate emblem and logo of Prestige Corp (PBH)

This daily price chart for Prestige Consumer Healthcare (PBH) reflects metric levels at 1.05. The business relies on an efficient fabless model, leveraging the high demand for hygiene products and the OTC segment. Strong market positioning is sustained by retailer loyalty and the pricing power of its well-known brands. Growth is driven by a strategy of acquiring legacy brands from pharma behemoths for subsequent marketing refreshes and global scaling.

Prestige Consumer Healthcare Inc (PBH) - Long-Term Debt to Equity from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for Prestige Consumer Healthcare (PBH)

- share price and expert price forecast:
Price Performance Chart Prestige Brands|PBH - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Prestige Consumer Healthcare, Inc.|PBH - Total Company Value
- company book value details:
Accounting Value of a Share Prestige Consumer Healthcare|PBH - Company Book Value|Market Cap to Net Assets Ratio prestigebrands.com|PBH - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital Prestige Consumer Healthcare|PBH - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio prestigebrands.com|PBH - Company Total Debt|Debts to Book Value Prestige Consumer Healthcare, Inc.|PBH - Company Long-Term Debt|Current Liabilities Prestige Consumer Healthcare|Intermediate Coverage Ratio prestigebrands.com
- earnings and valuation multiples indicators:
PBH - Net Profit
General company analysis:PBH (Prestige Brands)
Core merchandise of Prestige Consumer Healthcare, Inc.

For Prestige Consumer Healthcare (PBH), whose revenues depend on mass sales of OTC drugs, this indicator determines the business model's resilience to market downturns through an analysis of debt load. The trend of the long-term debt-to-equity ratio measures the proportion of loans with maturities exceeding one year, allowing investors to assess the default risk in the event of declining revenue from the sale of health products.

Analysis of competing companies

CVS: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MCK|Long-Term Debt to Capital AmerisourceBergen Corporation (COR)|Long-Term Debt to Equity Cardinal Health, Inc. CAH|Long-Term Debt to Capital Coefficient HSIC|WGRX - Long-Term Debt to Equity|111, Inc. (YI) - Long-Term Debt to Equity Ratio|RDGT: Long-Term Debt to Capital|Universe Pharma (UPC) - Long-Term Debt to Capital|BDRX (Biodexa) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio HK Pharma Digital (HKPD)|Long-Term Debt to Equity Ratio BIMI (BIMI Holdings)|CJJD - Long-Term Liabilities to Capital|Long-Term Debt to Equity Walgreens Boots Alliance, Inc. WBA